Ra Pharmaceuticals (RARX) 10-Q2019 Q3 Quarterly report

Filed: 7 Nov 19, 6:17am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: absence, accuracy, acquisition, affirmative, al, allege, ALS, AMG, amyotrophic, antitrust, appraisal, assumption, atrophy, attempt, attention, automatically, billion, brought, Center, concept, consent, consummate, consummated, consummation, contemplated, cost, Court, customary, declaratory, degeneration, demand, deposit, description, detail, discourage, disruption, District, diverted, Earl, Elaine, enjoin, eventually, exhibit, false, fiduciary, fulfillment, governmental, Healey, holder, illegal, impression, inability, indirect, injunctive, issuable, Jr, lawsuit, led, lower, merged, merger, merit, misleading, monetary, motor, neuron, nil, Orphan, overhead, party, pendency, plaintiff, PMDA, prevalent, prohibit, prohibiting, properly, proposal, propose, proposed, proposing, proxy, purported, putative, realize, recommendation, rendering, renegotiate, rescission, resolution, Sean, solicit, sought, structure, subcutaneously, superior, surrendered, survive, surviving, thereon, thereto, thousand, timeframe, UCB, unanimously, unspecified, vigorously, violation, vote, waiting, Wang, Wheby, wholly, writing

Removed: initiated, rare

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

RARX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATIONS OF CEO AND CFO PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report on Form 10-Q of Ra Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, Douglas A. Treco, Ph.D., President and Chief Executive Officer of the Company, and David C. Lubner, Executive Vice President and Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. (section) 1350, as adopted pursuant to (section) 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 7, 2019

/s/ Douglas A. Treco
Douglas A. Treco, Ph.D.
President and Chief Executive Officer

/s/ David C. Lubner
David C. Lubner
Executive Vice President and Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.